| Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies YZ Jiang, D Ma, C Suo, J Shi, M Xue, X Hu, Y Xiao, KD Yu, YR Liu, Y Yu, ... Cancer cell 35 (3), 428-440. e5, 2019 | 830 | 2019 |
| Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets Y Gong, P Ji, YS Yang, S Xie, TJ Yu, Y Xiao, ML Jin, D Ma, LW Guo, ... Cell metabolism 33 (1), 51-64. e9, 2021 | 340 | 2021 |
| Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response T Fu, LJ Dai, SY Wu, Y Xiao, D Ma, YZ Jiang, ZM Shao Journal of hematology & oncology 14 (1), 98, 2021 | 315 | 2021 |
| Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer Y Xiao, D Ma, S Zhao, C Suo, J Shi, MZ Xue, M Ruan, H Wang, J Zhao, ... Clinical cancer research 25 (16), 5002-5014, 2019 | 312 | 2019 |
| Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy F Yang, Y Xiao, JH Ding, X Jin, D Ma, DQ Li, JX Shi, W Huang, YP Wang, ... Cell metabolism 35 (1), 84-100. e8, 2023 | 286 | 2023 |
| Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial YZ Jiang, Y Liu, Y Xiao, X Hu, L Jiang, WJ Zuo, D Ma, J Ding, X Zhu, J Zou, ... Cell research 31 (2), 178-186, 2021 | 232 | 2021 |
| Comprehensive metabolomics expands precision medicine for triple-negative breast cancer Y Xiao, D Ma, YS Yang, F Yang, JH Ding, Y Gong, L Jiang, LP Ge, SY Wu, ... Cell research 32 (5), 477-490, 2022 | 214 | 2022 |
| Molecular subtyping of triple‐negative breast cancers by immunohistochemistry: molecular basis and clinical relevance S Zhao, D Ma, Y Xiao, XM Li, JL Ma, H Zhang, XL Xu, H Lv, WH Jiang, ... The oncologist 25 (10), e1481-e1491, 2020 | 152 | 2020 |
| Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence Y Xu, GH Su, D Ma, Y Xiao, ZM Shao, YZ Jiang Signal Transduction and Targeted Therapy 6 (1), 312, 2021 | 104 | 2021 |
| Emerging therapies in cancer metabolism Y Xiao, TJ Yu, Y Xu, R Ding, YP Wang, YZ Jiang, ZM Shao Cell metabolism 35 (8), 1283-1303, 2023 | 92 | 2023 |
| De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma DD Shi, MR Savani, MM Levitt, AC Wang, JE Endress, CE Bird, J Buehler, ... Cancer cell 40 (9), 939-956. e16, 2022 | 84 | 2022 |
| Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers TJ Yu, D Ma, YY Liu, Y Xiao, Y Gong, YZ Jiang, ZM Shao, X Hu, GH Di Molecular Therapy 29 (7), 2350-2365, 2021 | 82 | 2021 |
| Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing GT Lang, YZ Jiang, JX Shi, F Yang, XG Li, YC Pei, CH Zhang, D Ma, ... Nature Communications 11 (1), 5679, 2020 | 68 | 2020 |
| Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer L Jiang, C You, Y Xiao, H Wang, GH Su, BQ Xia, RC Zheng, DD Zhang, ... Cell Reports Medicine 3 (7), 2022 | 67 | 2022 |
| MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer SY Wu, Y Xiao, JL Wei, XE Xu, X Jin, X Hu, DQ Li, YZ Jiang, ZM Shao Journal for immunotherapy of cancer 9 (7), e002528, 2021 | 65 | 2021 |
| Establishment of patient-derived organoid models of lower-grade glioma KG Abdullah, CE Bird, JD Buehler, LC Gattie, MR Savani, AC Sternisha, ... Neuro-oncology 24 (4), 612-623, 2022 | 64 | 2022 |
| Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis S Zhao, D Ma, Y Xiao, YZ Jiang, ZM Shao European journal of surgical oncology 44 (4), 420-428, 2018 | 63 | 2018 |
| Breast cancer screening and early diagnosis in Chinese women R Ding, Y Xiao, M Mo, Y Zheng, YZ Jiang, ZM Shao Cancer biology & medicine 19 (4), 450-467, 2022 | 52 | 2022 |
| Molecular classification of hormone receptor-positive HER2-negative breast cancer X Jin, YF Zhou, D Ma, S Zhao, CJ Lin, Y Xiao, T Fu, CL Liu, YY Chen, ... Nature genetics 55 (10), 1696-1708, 2023 | 50 | 2023 |
| Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer S Zhao, XY Liu, X Jin, D Ma, Y Xiao, ZM Shao, YZ Jiang Theranostics 9 (17), 4935, 2019 | 49 | 2019 |